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favor of continuing with Mirena. Sensitivity analyses show
that first-line therapy for menorrhagia with Mirena is
likely to be less costly than hysterectomy under all rea-
sonable scenarios for women with menorrhagia.
CONCLUSIONS: Mirena provides a cost-beneficial al-
ternative to hysterectomy for women with menorrhagia
who are candidates for hysterectomy.
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Pharmacoeconomic analysis can facilitate formulary de-
cisions to select the most optimal therapy for overactive
bladder (OAB). Budgetary decisions and disease manage-
ment programs can be implemented only when drivers of
an analysis are identified and clearly understood.
OBJECTIVE: To determine drivers of cost and effective-
ness in a cost-effectiveness analysis of OAB treatments.
METHODS: Once-daily controlled release oxybutynin-
XL (OXY-XL) was compared with conventional oxybuty-
nin immediate-release (OXY-IR) and twice daily tolterod-
ine (TOL) in a decision tree model, using the payer per-
spective. Patient outcomes included percent of patients
completely continent, with rates determined through an ef-
ficacy-analysis of literature and clinical trial data, consid-
ering randomized controlled trials and open label safety
trials. Resource utilization was based on literature and ex-
pert opinion. Costs were categorized as drug, outpatient
care, laboratory, surgery/hospitalization and other (pads).
RESULTS: The average total 6 months expected cost for
producing one continent day is lower with OXY-XL
($22) than for OXY-IR ($25) and TOL ($43) and the ex-
pected success rate is highest for OXY-XL (52%) com-
pared to OXY-IR (46%) and TOL (32%), therefore,
OXY-XL is dominant. The primary driver for the model
is percent of patients completely continent, which im-
pacts directly upon the cost of outpatient care and sur-
gery. Drug, laboratory and other are all minor compo-
nents that did not significantly impact the costs. Results
are robust against all major assumptions tested in a com-
prehensive Monte Carlo sensitivity analysis.
CONCLUSIONS: Oxybutynin-XL is more cost-effective
than immediate release oxybutynin and tolterodine in
managing OAB. The key driver in the cost-effectiveness
ratio is the superior success rate, which lowers total med-
ical costs.
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OBJECTIVE: The purpose of this study was to derive the
cost-of-care for ischemic stroke by functional status and
create a decision analytic model to compare the cost-
effectiveness of citicoline to standard therapy.
METHODS: Expert data were gathered on the average
level of resource consumption by time period (acute hos-
pital, recovery, and maintenance) and functional status
(by Barthel Index score). Resource data was gathered
from 10 experts in ischemic stroke care using a modified
Delphi panel technique. Costs were derived from na-
tional claims databases and the literature. Included in the
model were direct medical costs associated with hospital-
ization, rehabilitation, home care and medications. Effec-
tiveness was based on the utility values of the Barthel out-
comes. Clinical outcomes of treatment with citicoline and
standard care, which included the use of tPA in 3.6% of
the cases, were taken from the literature. Cost of care and
cost-effectiveness was derived using a simple linear model.
RESULTS: The cost of care for ischemic stroke patients
during the maintenance period (3–12 months) was $4274
for patients with a Barthel Index score at 3 months be-
tween 95–100, $15,981 for patients with a score between
55–90, and $35,533 for patients with a score between 0–50.
It was estimated that the expected direct medical cost per
citicoline treated ischemic stroke patient for one year is
$37,066 compared with $38,456 for standard care. The
expected utility for a patient treated with citicoline was
0.547 utilities and for standard care it was 0.479 utilities.
CONCLUSION: A change in function following ischemic
stroke drives important cost differences. The use of citi-
coline in the treatment of ischemic stroke compared to
standard care both improves outcomes and reduces cost.
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OBJECTIVE: The purpose of this study is to perform a
meta-analysis of the cost-effectiveness of tirilazad mesy-
late in the treatment of aneurysmal subarachnoid hemor-
rhage (SAH) using primary data from four multinational,
randomized, double-blind, vehicle controlled phase III
clinical trials.
METHOD: The sample was made up of those patients
who at randomization had a severe initial neurograde
(score IV or V) and received either the gender-appropri-
ate dosage or vehicle. In each of the four trials, costs were
